Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,586.29
(
1.23%
)
US TECH 100
23,537.60
(
1.10%
)
Dow Jones
46,237.03
(
1.45%
)
Brent Oil
99.91
(
-7.61%
)
Bitcoin
70,310.17
(
3.64%
)
News Focus
News Focus
Post# of 257269
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 90348

Tuesday, 02/09/2010 5:28:42 AM

Tuesday, February 09, 2010 5:28:42 AM

Post# of 257269
jbog et al Re: D-mab and ONJ

In the three completed trials of D-mab vs Zometa in metastatic cancer (the first three rows of the table in #msg-46432335), the aggregate rate of ONJ is 1.8% for D-mab vs 1.3% for Zometa.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today